Showing results (221-230 of 255) with videos related to
Sort By:
Pageof 26
Molecular Cancer|November 13, 2024
The PI3K-AKT-mTOR axis persists as a therapeutic dependency in KRASG12D-driven non-small cell lung cancerW J McDaid, L Wilson, H Adderley, et al.ESMO Open|November 18, 2025
Immunotherapy beyond progression combined with platinum-based chemotherapy after primary resistance to first-line immunotherapy in patients with advanced NSCLC and PD-L1 ≥50A De Giglio, L Zullo, A Di Federico, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2017
SELECT-2: a phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of patients with advanced or metastatic non-small-cell lung cancerJ-C Soria, A Fülöp, C Maciel, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 16, 2011
Sequential research-related biopsies in phase I trials: acceptance, feasibility and safetyC A Gomez-Roca, L Lacroix, C Massard, et al.Journal for Immunotherapy of Cancer|August 22, 2020
Dose escalation phase 1 study of radiotherapy in combination with anti-cytotoxic-T-lymphocyte-associated antigen 4 monoclonal antibody ipilimumab in patients with metastatic melanomaCeline Boutros, Nathalie Chaput-Gras, Emilie Lanoy, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 27, 2017
An exploratory, open-label, randomized, multicenter study to investigate the pharmacodynamics of a glycoengineered antibody (imgatuzumab) and cetuximab in patients with operable head and neck squamous cell carcinomaS Temam, J Spicer, F Farzaneh, et al.ESMO Open|December 25, 2021
IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancerO Molinier, B Besse, F Barlesi, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 26, 2017
Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) programC Leduc, J P Merlio, B Besse, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 8, 2017
Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasmaA K Krug, D Enderle, C Karlovich, et al.Clinical Lung Cancer|March 19, 2021
RADIORYTHMIC: Phase III, Opened, Randomized Study of Postoperative Radiotherapy Versus Surveillance in Stage IIb/III of Masaoka Koga Thymoma after Complete Surgical ResectionC Basse, A Botticella, T J Molina, et al.Pageof 26